Outcomes are the product of human observation and state-of-the-art reporting, including the use of barcode scanning, mobile apps and seamless integration with other programs. Our program designs have put Bracket at the forefront of electronic Clinical Outcomes Assessments.
As a proud and active member of the Critical Path Institute’s (C-Path) ePRO Consortium, Bracket collaborates with industry leaders to advance the application and value of electronic modalities in clinical endpoint assessments.
Bracket’s Rater Station℠, an enhanced type of electronic Clinician-Reported Outcome (eClinRO), uniquely features intelligent design that provides added clinical value and quality control. The Rater Station℠ is an FDA 21 CFR part 11 and EMEA Annex 11 compliant computer device that has been used in dozens of pivotal worldwide studies.
The Rater Station℠ intelligent design improves interview quality while reducing administration and scoring errors. Outcomes can be programmed to enforce a structured interview format, and can be applied to a wide range of therapeutic areas and Clinician-Reported Outcomes.
Bracket’s industry-leading Rater Station℠ solution provides clients the following advancement in eClinRO services:
Bracket’s eCOA platform can be configured for use by parents, teachers, caregivers, and other non-clinical observers of a patients activities or symptoms.
Multiple deployment methodologies to meet unique needs of Observer-Reported Outcomes. Our solution supports the use of telephone-based IVR reporting, web-based questionnaires, and mobile-device based applications.
Low cost solutions supported by Bracket’s Bring Your Own Device (BYOD) mobile app solution. Bracket’s mobile app is available on iOS and Android, so you can use what works best for you.
Scalable reporting and data management capabilities to support large dataset analysis and industry-compliant data delivery methods.
Developed by Professor Keith Wesnes, the CDR System™ has become the industry standard for automated assessment of cognitive function in clinical trials for the last 20 years. Supported by an unparalleled publication record and the most comprehensive neuropsychopharmacology databases ever assembled, the CDR System℠ provides clients with the most sensitive set of tests ever developed to assess improvements and impairments in cognitive function.
The CDR System℠ assesses the major domains of cognitive function that are vulnerable to aging, fatigue, disease, pathology, trauma, diet and pharmaceuticals.
Used in more than 1,200 trials across 50 indications and available in over 30 languages, the CDR System℠ works in all clinical settings with any patient population throughout the drug development process.